RT @sonbol_bassam: As highlighted below—we need to see OS data. Just 24 hrs ago, CM577 reminded us that DFS benefit doesn’t guarantee OS be….

RT @SuyogCancer: Whole discussion on matterhorn Trial was exactly how it should NOT be at such prime conference . Not a single issues with….

RT @JCO_ASCO: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic #ColorectalCa….

RT @ForePlayPod: 🏡 RIGGS EXPERIENCE GIVEAWAY 🏡. One winner and their friend will get a FREE round trip to Pinehurst for 2 nights & 2 rounds….

Phase 1b results from CRDF second line KRASm CRC now published in @CCR_AACR . RP2 1st study CRDF-004, to open soon. Congrats to our co-authors and patients @MayoCancerCare @GIcancerDoc.

@GIcancerDoc @MayoCancerCare @GIcancerDoc.

Our paper is now published in JNCCN looking @ adjuvant chemo prescribing patterns post IDEA @GIcancerDoc @MayoCancerCare . New account fyi (old was hacked).